CLINICAL_TRIALS
trial_result
· 2019-10-08
Clinical Trial Update: Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia [Phase 2]
Summary
Phase 2 clinical trial evaluating azacitidine and lenalidomide in relapsed/refractory acute myeloid leukemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Colorado, Denver | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-10-08